CRVSCorvus Pharmaceuticals, Inc.

$14.74

Who owns CRVS

164 institutions reported holding CRVS for 2026Q1, together 78% of the company, more than the 123 a quarter earlier.

164

Institutions reporting a position · as of 2026Q1 · up from 123 the quarter before

Shares held by institutions
70.0M

Shares held by institutions · 78% of the company · long US equity positions only, as reported on Form 13F

Reported value
$1.02B

Reported value · at 2026-03-31 prices, not today's

Top 5 holders
27%

Top 5 holders · of the whole company, between five filers

Details
Reporting quarter2026-03-31
2026Q1
Quarters on record
41
New positions
64
Positions exited
27
Added to
54
Reduced
29
Top 10 holdersof the company
42%
Institutional ownership by quarter, 2016Q1 to 2026Q1
QuarterFilersSharesReported value
2026Q116470.0M$1.02B
2025Q412346.7M$359M
2025Q310141.7M$307M
2025Q29141.8M$167M
2025Q18836.3M$115M
2024Q48537.7M$202M
2024Q36230.0M$159M
2024Q24727.6M$50M
2024Q14717.9M$32M
2023Q44819.2M$34M
2023Q35219.2M$28M
2023Q25219.5M$45M
2023Q13720.8M$19M
2022Q44121.4M$18M
2022Q34822.1M$18M
2022Q24725.6M$25M
Largest reported holders, 2026Q1
HolderShares% of companyValue
ORBIMED ADVISORS LLC7.2M8.0%$105M
BlackRock Inc.6.2M6.8%$90M
VANGUARD GROUP INC4.5M5.0%$65M
STATE STREET CORP3.6M4.0%$52M
ADAMS STREET PARTNERS LLC3.3M3.6%$48M
PRICE T ROWE ASSOCIATES INC /MD/2.9M3.2%$43M
Vivo Capital, LLC2.8M3.1%$41M
MORGAN STANLEY2.5M2.8%$37M
Deep Track Capital, LP2.5M2.8%$36M
WELLINGTON MANAGEMENT GROUP LLP2.3M2.6%$34M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…